Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
33%
Ph phase_4
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
2(66.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Terminated(1)
Other(1)

Detailed Status

Not yet recruiting1
unknown1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 42 (66.7%)

Trials by Status

not_yet_recruiting133%
unknown133%
withdrawn133%

Recent Activity

0 active trials
Showing 3 of 3
not_yet_recruitingphase_4

Non Inferiority KawasakI Trial With Anakinra

NCT06697431
unknownphase_4

Early and Late Prognosis in Patients With Guillain-Barre Syndrome

NCT06041451
withdrawnphase_3

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

NCT03749096

Clinical Trials (3)

Showing 3 of 3 trials
NCT06697431Phase 4

Non Inferiority KawasakI Trial With Anakinra

Not Yet Recruiting
NCT06041451Phase 4

Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Unknown
NCT03749096Phase 3

Randomized Placebo Controlled Trial of IVIg in Glycine Receptor Antibody Positive Stiff-person Syndrome

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3